Diamyd Medical announces today that the company has signed an agreement with

Inclinix Inc., North Carolina, for accelerated recruitment of children and

adolescents recently diagnosed with type 1 diabetes in the US Phase III study of

the diabetes vaccine Diamyd^®.

Diamyd Medical is conducting a global Phase III program with the diabetes

vaccine Diamyd^®, including in total 640 children and adolescents with

recent-onset type 1 diabetes. The program is composed of one study in the US and

one parallel study in nine countries in Europe. The US recruitment effort will

soon be launched together with Inclinix Inc., under the name DIAPREVENT.

- Our agreement with Inclinix is performance based and targets to enable filing

for market approval in the US during 2011, which secures our time-to-market

projections for the Diamyd^® vaccine, says Elisabeth Lindner, President and CEO,

Diamyd Medical.

The US Phase III study is rapidly expanding its number of sites from 13 to at

least 43 sites. The new sites are pediatric diabetes clinics for enrollment of

patients from 10 years of age. The highest incidence of type 1 diabetes is in

the age range 10-15 years. Inclinix has an excellent track record in patient

recruitment for type 1 diabetes in the US and is working through targeted

internet advertising, social media networking, professional regional recruitment

managers and regional referrals of patients to the study clinics.

- We are pleased that Diamyd Medical has chosen Inclinix as their enrollment

partner for this important study. We look forward to the opportunity to

contribute to the development of the Diamyd^® vaccine and thereby make a truly

global impact on the pediatric medical community, says J. Tobin Geatz, President

and CEO, Inclinix.

The purpose of the study is to determine whether Diamyd^® can preserve the body's

own insulin producing capacity in persons recently diagnosed with type 1

diabetes. Maintaining the insulin producing capacity could result in simpler

treatment and a better blood sugar balance, which in turn could reduce the risk

of both short-term and long-term complications typically associated with

diabetes.

For additional information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)

Tel: +46 (0)8 661 0026

For pictures and press material, please contact:

Andreas Ericsson, Diamyd Medical AB (publ.)

andreas.ericsson@diamyd.com

Tel: +46 (0)8 661 0026

About Inclinix

Inclinix, Inc. is a global enrollment Contract Research Organization (CRO)

specializing in customized Phase I - IV clinical trial enrollment solutions.

Inclinix services deliver productive investigative sites and qualified patients

for Sponsors, resulting in successfully completed clinical trials for the

pharmaceutical, biotech and medical device industries. Comprehensive enrollment

solutions include site recruitment, patient recruitment, clinical and medical

marketing communications, patient compliance and education, and the InSite

ScreenerT and InSite Patient TrackerT for comprehensive patient qualification

and retention. Since 1999, Inclinix (formerly PharmaTech Solutions, Inc.) has

participated in over 400 clinical trials in over 130 indications. Inclinix

corporate headquarters is located in Wilmington, North Carolina with additional

offices in Annapolis, Maryland, and Gothenburg, Sweden.

Inclinix contact:

Kristin Sacre, Corporate Marketing Manager, Inclinix, Inc.

ksacre@inclinix.com

Tel: +1-910-332-2682

About Diamyd Medical

Diamyd Medical is a Swedish diabetes company focusing on

the development of pharmaceuticals for the treatment of autoimmune diabetes and

its complications. The company's most advanced project is the GAD-based drug

Diamyd^® for type 1 diabetes. Phase III trials for this drug are in progress in

both Europe and the US. In addition, the company has initiated clinical studies

in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery

System (NTDDS). The company has also out-licensed the use of GAD for the

treatment of Parkinson's disease. The company currently has three clinical-phase

products.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq

OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)

administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Further information is available on the company's website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities

Markets Act, the Swedish Financial Instruments Trading Act, or the requirements

stated in the listing agreements.



Diamyd Medical AB (publ.)

Linnégatan 89 B,

SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68

E-mail: info@diamyd.com. VAT no: SE556530-142001.